Neoplasia/BPH

	Polish Brachytherapy Society clinical recommendations and expert consensus on radical high-dose-rate brachytherapy for prostate cancer. J Contemp Brachytherapy Chyrek AJ, Hetna, Kukie, Lelek P, Kluska A, Romaniszyn A, Samo, Burchardt W, Cisek P, Krzysztofiak T, Kolbusz M, Kazalski D, Filipowski T, Kazberuk D, Szmigiel-Trzcin'ska A, Celarek K, Madej P, Konat-Ba Ska K, Lichon' K, Matys R, Bilski M, Burchardt E, Stankiewicz M, Chiche, Wojcieszek P. PMID: 42232852 [PubMed]
	Precision Diagnostics in Prostate Cancer Treatment (PREDICT): A Phase II Multiarm Biomarker-Based Study (Alliance A032102). JCO Oncol Adv Chen YW, Bobek O, Heller G, Berg S, Tan A, Zhao SG, Galsky M, Rosenberg J, Beltran H, McKay RR. PMID: 42232816 [PubMed]
	Insights from a rare case of eosinophilic solid and cystic renal cell carcinoma: Diagnostic highlights and therapeutic directions. Urol Case Rep Qiu J, Ni L, Yu L, Yang Y. PMID: 42232815 [PubMed]
	Segmentation regularized training for multi-domain deep learning registration applied to magnetic resonance-guided prostate cancer radiotherapy. Phys Imaging Radiat Oncol Madhavan S, Gui C, Bosma L, Simeth J, Jiang J, Côté N, Rezaeian NH, Nagar H, Brennan V, Tyagi N, Veeraraghavan H. PMID: 42232230 [PubMed]
	The efficacy and safety of darolutamide combination therapy in advanced prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol Cao X, Li D, Han Z, Li Z, Chu J, Song C, Huang H, Yuan H, Wang Z. PMID: 42232182 [PubMed]
	GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer. EJNMMI Res Tanegashima T, Shiota M, Doi A, Tatarano S, Kamba T, Igawa T, Masumori N, Uemura H, Kamoto T, Higashijima K, Mitsunari K, Uemura H, Sumiyoshi T, Isoda T, Ishigami K, Tokunaga S, Eto M. PMID: 42230449 [PubMed - as supplied by publisher]
	Clinical Characteristics and Outcomes of Immune Checkpoint Inhibitor Associated Renal Toxicities: A Retrospective Pan-Cancer Cohort Study. Clin Ther Trivedi C, Contini J, Adams M, Steuer RZ, Jain SK, Chu JJ, Gupta SR, Petruzzelli C, Malani K, Park W, Constantinou M, Lagos G, Min M, Hadfield MJ. PMID: 42230259 [PubMed - as supplied by publisher]
	Inflammation-Driven Transcriptional Reprogramming in Prostate Cancer: Convergence of NFÎºB, JAK/STAT3, and Epigenetic Remodeling in Castration-Resistant Disease. Cancer Lett Krishna M, Garg P, Horne D, Salgia R, Singhal SS. PMID: 42229824 [PubMed - as supplied by publisher]
	Beyond GnRH analogues: The Renaissance of Estrogens in Prostate Cancer Management. Fr J Urol Matthys M, Klein C, Roumeguère T, Bladou F, Robert G, Tombal B. PMID: 42229758 [PubMed - as supplied by publisher]
	Reply: UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A 24-Month Duration of Response Results from the Phase 3 ENVISION Trial. J Urol Prasad S. PMID: 42229364 [PubMed - as supplied by publisher]
	Targeting mitochondrial metabolism in renal cell carcinoma with melatonin: Preclinical evidence and clinical perspectives. Tissue Cell Noroozi-Karimabad M, Alimohammadi M, Mafi A, Hedayati N, Razavi FT, Cho WC, Mohammad-Sadeghipour M, Farahani N, Entezari M, Daneshi S, Hushmandi K, Taheriazam A, Hashemi M. PMID: 42229285 [PubMed - as supplied by publisher]
	Magnetic resonance imaging-guided radiotherapy for prostate cancer: A systematic review of the literature. Cancer Radiother Adoum SL, Baty M, Masson I, Le Guévelou J, Lafond C, Créhange G, Chapet O, Pasquier D, Riou O, Truc G, Salem N, Simon JM, de Crevoisier R. PMID: 42229011 [PubMed - as supplied by publisher]
	Impact of radiotherapy timing on survival and radiotoxicity outcomes in localized prostate cancer: a retrospective cohort study. Radiol Med Oliveira-Sousa R, Castro C, Carriço ÍR, Leite-Silva P, Macedo-Silva C, Bravo I, Santos J, Jerónimo C, Miranda-Gonçalves V. PMID: 42228040 [PubMed - as supplied by publisher]
	Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer. Clin Cancer Res Smoragiewicz M, Bernard-Tessier A, Linch M, Shen J, Shore ND, Parikh O, Chi KN, Sokolova AO, Culine S, McKean M, Gleave M, Devitt ME, Zhi E, Gong J, Landrette S, Colasanto M, Patel V, Gao X. PMID: 42227954 [PubMed - as supplied by publisher]
	One-year Follow-up after US-guided Transperineal Focal Laser Ablation of Localized Prostate Cancer: Worldwide Registry Study. Radiology de Bie KCC, Cornud FC, Walser EM, van Riel LAMJG, Regusci S, Martins Favre M, Zimmer RE, Galiano M, Manenti G, Micillo A, Oddens JR. PMID: 42227864 [PubMed - in process]
	Diagnostic accuracy of contrast-enhanced ultrasound for detecting renal cancer: a systematic review and meta-analysis. Med Ultrason Xu R, He Y, Xie X, Chen G. PMID: 42227142 [PubMed - as supplied by publisher]
	A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non-muscle-invasive bladder cancer. Nanomedicine (Lond) Narayan A, Leibrandt RC, Lee JS, Dall'Era MA, Whitson JM, Chandrasekar T, Braun A, Mossanen M, Li H, Lara PN Jr, Lam KS, Pan CX, Parikh M. PMID: 42226594 [PubMed - as supplied by publisher]
	Study adds new evidence on use of salvage focal therapy for radio-recurrent prostate cancer. Cancer Lawrence L. PMID: 42226545 [PubMed - in process]
	Impact of Absolute PSA Value and Relative PSA Response Rate on Overall Survival in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. Int J Urol Suzuki T, Fukuda T, Nishizaki K, Fukui K, Yoshioka S, Kaizuka Y, Nagasawa S, Togo Y, Motoki Y, Tanaka W, Ueda Y. PMID: 42226505 [PubMed - in process]
	Development and validation of a machine learning model for predicting distant metastasis in patients with renal cell carcinoma: a population-based study. World J Surg Oncol Cheng C, Peng X, Qiu R, Ma H, Gui M, Shi R. PMID: 42226290 [PubMed - as supplied by publisher]

Articles 1 - 20 / 188313

Page 1 of 9416



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy